The Board of Directors of Zydus Lifesciences Limited, at their meeting held on May 19, 2026, approved the audited financial results for the quarter and year ended March 31, 2026. During the quarter ended March 31, 2026, the company reported revenue from operations of ₹37,409 million, compared to ₹22,836 million in the previous quarter (ended December 31, 2025) and ₹58,196 million in the corresponding quarter of the previous year (ended March 31, 2025).

Export to Sheets

Note: The percentage variations are calculated based on the figures provided in the company’s financial results filing.

Zydus Lifesciences Limited is a prominent global pharmaceutical company headquartered in Ahmedabad, India, specializing in the research, development, production, and distribution of a wide range of pharmaceutical products. The company’s diverse portfolio encompasses active pharmaceutical ingredients (APIs), human formulations, vaccines, biosimilars, animal health products, and consumer wellness items. With a legacy spanning over 70 years, Zydus has established a strong international presence, with manufacturing and research facilities located across India, the US, and Brazil.

In 2025, Zydus Lifesciences continued to expand its global footprint through strategic acquisitions and partnerships, including the acquisition of Agenus Inc.’s biologics manufacturing business to enhance its production capabilities. The company has been actively involved in advancing its research pipeline, receiving various regulatory approvals for its generic and novel drug candidates. Recent developments in 2026 include the announcement of a share buyback program and the acquisition of Assertio Holdings to further strengthen its market position. While the company has numerous institutional investors, specific details regarding famous individual investors are not prominently highlighted in recent 2025-2026 financial updates.